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Raul Altman1* and Claudio Daniel Gonzalez2Abstract
Aims: Although quantitative anti-FXa assays can be used to measure rivaroxaban plasma levels, they are not widely
performed or available. We aimed to tentatively determine the cut-off for thromboembolism and bleeding prevention
based on the clotting effect of non-rivaroxaban conjugate-activated FX plasma levels in patients with rivaroxaban using
a coagulometric method.
Methods and results: Rivaroxaban was added in vitro to normal plasma at a range of 0 to 241 μg/L to cover expected
peak and trough levels. Rivaroxaban chromogenic (μg/L) and RVV-confirm as a ratio were determined. Patient plasma
samples were assayed with the RVV-confirm reagent. The appropriate rivaroxaban plasma concentration to inhibit
clotting mechanisms was based on the remaining FXa in plasma, which was expressed as the ratio of patients/
normal, R-C. There is a high correlation between R-C in vitro and spiked normal plasma rivaroxaban concentration
(R-Square 0.910, linear equation; 0.971 quadratic equation, p < 0.0001 for both) but not with plasma rivaroxaban
chromogenic assays. We propose a cut-off R-C value of 1.65 and 4.5 for safety. Based on the proposed therapeutic
range, in 158 assays performed in 58 patients, 6.3 % assays were above the level of bleeding tendency at the peak
(R-C 5.39 ± 1.01, median 5.13) and 42 % assays were below the prevention cut-off at the trough (R-C 1.31 ± 0.18,
median 1.35).
Conclusions: RVVconfirm® is fast and sensitive to measure the effect of rivaroxaban. Clinical studies are needed to
establish whether this cut-off is useful for identifying patients at increased risk of hemorrhage or those who exhibit
a low level of anticoagulation.
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The well-established benefits of anticoagulant therapy
are significantly hampered by the possibility of throm-
boembolism or major and sometimes fatal bleeding com-
plications. These adverse effects can range from simple
external skin bruising and bleeding (epistaxis, gastroduo-
denal bleeding, pulmonary complications) to problems in
vital organs, including temporary or permanent impair-
ment of function (intracranial hemorrhage or embolism),
and possibly death. Despite their importance, as well as* Correspondence: draltman@arnet.com.ar
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creativecommons.org/publicdomain/zero/1.0/the known benefit of warfarin, appropriate medication use
remains a challenge for patients. Indeed, for vitamin K an-
tagonists, the rates of non-adherence range from
22–58 %. This rate is significant because 34 to 43 % of
patients taking warfarin are not in therapeutic range
[1], which results in poor clinical outcomes [2]. The
history of non-adherence is likely underrepresented in
trial outcomes research. As a real world consequence,
patients receiving chronic warfarin therapy who have
poor anticoagulation control are at increased risk for
adverse events [3]. In large studies, the rate of prema-
ture discontinuation of new direct oral anticoagulants
(DOACs) for no apparent reason is reported to beAccess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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important benefit of DOACs is that they do not require
routine coagulation control due to their predictable
pharmacokinetic and pharmacodynamic profiles [4].
However, there is agreement that some clinical circum-
stances require measuring the anticoagulant effect of the
DOAC (5) (e.g., preparation for surgery; major bleeds,
compliance and/or effect checks, renal impairment). How-
ever, concentrations of DOACs and their effect on coagu-
lation are dependent on the pharmacokinetics of the drug
and on the concomitant presence of potent P-glycoprotein
inhibitors or agonists. To improve efficacy and safety, dose
adjustment based on the therapeutic effect may be more
appropriate than fixed-dose therapy. The anti-Factor Xa
method using chromogenic assay and expressed as μg/L
measures the drug concentration and not the intensity of
the drug’s anticoagulant activity, and a higher or lower
than expected DOACs plasma level does not necessarily
indicate an increased risk of bleeding or thrombotic com-
plications [4, 5].
Then it is imperative in daily practice to periodically
evaluate dosage to ensure safety and effectiveness. Coagu-
lometric tests based on Russell’s viper venom has been
proposed as potential methods to evaluate DOACs as they
are sensitive to both classes of these inhibitors [6–8].
Methods
Normal donors
Twenty healthy volunteers (12 women and 8 men) with
no history of thromboembolic or hemorrhagic diseases,
cardiac, renal, hepatic, or malignant diseases, were
required to be drug free for 10 days before the study.
Only platelet poor plasma from subjects with a normal
prothrombin time, activated partial thromboplastin time
and thrombin time that fulfilled the inclusion criteria
were used.
Patients
This study included patients with no history of hemorrhagic
diseases receiving prolonged oral therapy with rivaroxa-
ban. The review board of the Centro de Trombosis de
Buenos Aires approved the study. A total of 158 at peak
and 158 at trough measurements of DVVconfirm were
performed in 58 patients (36 men, 22 women; mean
age, 66.8 ± 14.8 years; median age, 69 years). Patients
were referred to our clinic after their own physician
recommended drug use due to deep venous thrombosis
(26 patients, 3 with pulmonary embolism), portal vein
thrombosis (1 patient), mesenteric vein thrombosis
(1 patient), atrial fibrillation (30 patients 1 patient with
coronary stenting). Fifty patients were treated with
20 mg rivaroxaban per day, and 8 with 15 mg/day.
Medication was taken at the same hour each morning.
Patients were required to have received therapy for≥14 days before entering the study. Study complies
with the Declaration of Helsinki and informed consent
was obtained from all patients. Among the 58 patients
Rivaroxaban plasma concentration (using chromogenic
assay and expressed as μg/L) at peak and at trough were
performed in 30 patients (10 men, 20 women) and com-
pared with DVVconfirm assay (data were expressed as
ratio of patient plasma/normal plasma values) (R-C).Hemostasis tests
Venous blood was drawn from the antecubital vein and
mixed with 0.11 mol/L sodium citrate (1:10 v/v). Blood
samples for assays were obtained at the peak of drug ac-
tivity (mean, 2.05 ± 0.23 h; median, 2.1 h) and during
the activity trough 0–2 h before the next dose (mean,
23.6 ± 1.19 h; median, 23.7 h). Tests were performed
within 3 h of sampling. Platelet-poor plasma (PPP) was
obtained by centrifuging blood samples at 900 × g for
15 min. DVVconfirm® was used to measure citrated PPP
using the reagents from Sekisui Diagnostics (Stanford,
USA) following the manufacturer’s indications using a
coagulometer ST4 (Diagnostica Stago, Asnieres, France).
DVV-confirm assay results are reported in seconds of time
to clot and the seconds are used to determine the ratio
expressed as R-C values.
Rivaroxaban-containing calibrators (241 μg/L of rivar-
oxaban) were reconstituted with 1 ml pooled normal
plasma to obtain a concentration of 241 μg/L, which
was further diluted serially with the same pooled normal
plasma to obtain concentrations between 0 and 241 μg/L.
For the in vitro spiking studies rivaroxaban-containing
calibrators (purchased from Stago (Diagnostica Stago,
Asnieres, France) were used for both the DVV-confirm
and the chromogenic assays.
Rivaroxaban chromogenic assays were performed ac-
cording to Samama et al. [9] using STA Liquid anti-FXa
assay controls and calibrators from Stago (Diagnostica
Stago, Asnieres France) with a STA analyzer.Statistical analysis
Qualitative data are expressed as percentages, whereas
quantitative data are shown as mean ± SD. The differences
between “peak” vs. “trough” values were explored using a
paired Student’s t-test. The correlation between rivaroxaban
concentration and R-C was determined using several differ-
ent models, including the linear Pearson approach as well
as other, more complex, models (exponential, quadratic,
cubic, etc.). The corresponding R-square coefficients were
obtained. The simplest model providing the most signifi-
cant R-square coefficient (compared with the linear Pearson
model) was considered to have the best fit. All statistical
analyses were performed using SPSS, and p-values below
0.05 were considered significant (two-tailed).
Table 1 Model summary and parameter estimates
Equation Model summary Parameter estimates
R square F df1 df2 Sig. Constant b1 b2
Linear .901 100.405 1 11 .000 .371 .031
Quadratic .971 169.965 2 10 .000 1.195 .000 .000
Dependent variable: R-C
The independent variable is Rivaroxaban concentration
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In vitro spiking studies
For In vitro spiked studies known concentration of rivar-
oxaban was used. The correlation between rivaroxaban
concentration and R-C using a simple linear correlation
yielded an R-square coefficient of 0.910 (p < 0.0001) (Fig. 1);
using a quadratic model, the R-square coefficient was
0.971 (p < 0.0001) (Fig. 1). The corresponding parame-
ters and constant are depicted in Table 1. As mentioned
above, the “goodness of fit” was significant using the
quadratic approach. Overall, these correlation coeffi-
cients indicate an excellent correlation between rivarox-
aban concentration and R-C test. As seen in Fig. 1, it
seems feasible to interpret the curvilinear quadratic graph
as being composed of two linear components (dashed
lines). This finding warranted further exploration.
Measurements in plasma patients receiving oral therapy
with rivaroxaban
The correlation between rivaroxaban concentration mea-
sured as aFXa in patients plasma and R-C is shown in
Table 2. The correlation between plasma rivaroxaban con-
centration and R-C at trough (24 h of drug ingestion)
yielded a R coefficient of 0.688 (R2: 0.473, p < 0.001) at the
linear model; at peak (after 2 h of drug ingestion) the
strength of the association was weaker, with an R linear
correlation coefficient of 0.39 (R2: 0.15; p = 0.03).
Rivaroxaban-test coagulometric method
To evaluate the rivaroxaban coagulometric method, where
the patient should be at both peak and trough times theFig. 1 In vitro spiking studies. Correlation between rivaroxaban
concentration and R-C. For In vitro spiked studies known of rivaroxaban
concentrations between 0 and 241 μg/L were used. Statistically
significant R-Squares of 0.910 (p < 0.0001) using a linear correlation
and an R-Square of 0.971 using a quadratic equation (p < 0.0001)
indicate an excellent correlation between rivaroxaban concentration
and R-C test. Apparently the curved line has two lineal components
(dashed lines)Russel’s viper venom-confirm® method was used in 158
plasma samples from 58 patients. Considering cut-offs of
1.65 and 4.5 as limits of therapeutic levels, 10 determi-
nations (6.3 %) (Fig. 2) were above the bleeding risk level
(R-C 5.39 ± 1.01, median 5.13) and 66 tests (42 %) (Fig. 3)
were below the theoretical prevention cut-off (R-C 1.31 ±
0.18, median 1.35).
Discussion
Although quantitative anti-FXa chromogenic assay has
been proposed to measure rivaroxaban plasma levels for
patients under rivaroxaban therapy, it is not widely per-
formed or available [4–6]. With the absence of widely
accepted therapeutic target levels, speculative cut-off
levels for safety and prevention were used in the current
manuscript.
Taking into account the hemorrhagic level of patients
with Factor X deficiency as well as their haemostatic
level, this prospective study based on an empirically
validated numerical model was designed to investigate
cut-off levels in patients receiving rivaroxaban therapy.
Rivaroxaban blocks FX activity, and the unbounded
FXa remains available in the clotting system. Even if
clinical trials prove the safety of the fixed dose regimen,
patients should get frequent follow-up attention by
nurses regarding any side effects that do not occur in
daily practice.
The cut-off for prevention was based on the plasma
activity of vitamin K-dependent clotting factors mea-
sured in patients on warfarin, a treatment with a target
INR range of 2.5 ± 0.3. In Dargaud et al. study [10]
the Factor X level in patients without complications was
19 ± 10 IU dL−1, and the level in patients with throm-
bosis was 16 ± 5 IU dL−1. Moreover, bleeding is infre-
quent in patients with F X levels above 20 % [11].Table 2 Chromogenic substrate test
Correlation at trough (24 h) R-C
aFXa Rivaroxaban 0,6881
P = 0.0001
Correlation at peak (2 h)
aFXa Rivaroxaban 0,3908
P = 0.033
Coefficient of correlations between R-C and rivaroxaban in plasma
R-C Ratio patient plasma / normal plasma
Fig. 2 DOAC-test coagulometric method. Ten plasmas among 158
assayed for R-C value were above R-C of 4.5 proposed as cut-off for
increased bleeding tendency. Patients were above range at peak time
only. The value at peak R-C is 5.39 ± 1.01, with a median of 5.13. Peak
vs. trough values: p < 0.001
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speculate on the safety of patients undergoing rivarox-
aban therapy. Bleeding symptoms tended to correlate
with FX levels: mild (>6–10 %), moderate (1–5 %) or
severe (<1 %). Severe clinical symptoms, such as intra-
cranial hemorrhage, gastrointestinal bleeding and
hemarthrosis, are not common in patients with FX
levels >2 % [12]. Patients with FX levels <10 % present
with mucocutaneous bleeding, whereas those with
moderate to severe deficiency may have symptomsFig. 3 Sixty six plasma samples among 158 assayed for R-C value
were below an R-C of 1.65, which was proposed as the cut-off for
increased pro-thrombotic tendency. Three patients were below
range at both peak and trough. The value at trough R-C is 1.30 ±
0.18, with a median of 1.35. Peak vs. trough values: p < 0.001such as hemarthrosis, intracranial hemorrhage, and
gastrointestinal bleeding. These patients experience
spontaneous bleeding when their plasma Factor X con-
centration is below 1 % [13, 14]; patients with higher
levels of Factor X can also bleed in a traumatic situ-
ation. Patients with amyloidosis [15] developed severe
gastrointestinal bleeding as a result of a significant
decrease in Factor X levels, but a patient who pre-
sented with spontaneous retroperitoneal bleeding had
22 % FX activity [16].
Based on these data and that reported in our previous
publication [7], Factor X concentration curves were cre-
ated. Based on these curves, 1.56 % FX corresponded
with a R-C of 4.5, and 20 % FX corresponded with a R-C
of 1.65. These values were designated as cut-offs for
safety and thromboembolic prevention in the current
study.
An optimal drug level should be obtained to achieve
the correct balance between antithrombotic efficacy and
bleeding risk. Brummel-Ziedins et al. [17] found a marked
interindividual variation of FXa generation in a healthy
population (from 49 to 163 %) and in individuals with a
known DVT history (from 58 to 174 %). with statistically
significant differences between groups. These differences
were also related to gender, BMI and oral contraceptives
[17]. Patients taking 20 mg rivaroxaban had a daily con-
centration peak that varied between 177 and 361 μg/L
and a trough of 9.02 to 147 μg/L [18, 19]. Similarly, at a
dose of 10 mg, the daily concentration peak was 75.1 to
177 μg/L and a trough of 1.35 to 37.2 μg/L. These inter-
individual variations were also observed with other
DOACs [20, 21].
In the current study based on in vitro spiking studies,
it is apparent that the DOAC-rivaroxaban coagulometric
method is suitable for measuring non-rivaroxaban boun-
ded plasma-activated Factor X ex vivo. The results ob-
tained with spiked plasma may not be similar to those
obtained from ex vivo patient plasma due to the absence
of drug metabolites. At high concentrations, rivaroxaban
or its metabolites may have additional effects on clotting
mechanisms that are currently unknown [22].
Thus, the question arises over whether rivaroxaban
concentrations measured by an anti-FXa chromogenic
assay indicate the extent of clotting inhibition mecha-
nisms as well as a coagulometric assay. Given the marked
variation between healthy individuals with thrombosis as
well as patients with liver, kidney or bowel disease, one
must assume that a significant fraction of patients will be
exposed to either very low or very high drug levels [23].
Safety in daily practice could be improved with an easy-to-
use coagulometric method. In the absence of widely
accepted therapeutic target levels, we speculate cut-off
points for identifying patients with an increased risk of
hemorrhage, R-C ≥4.5, or those exhibiting a low
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offs of a pro-thrombotic state. Using the proposed
therapeutic range for 158 plasma samples, 10 (6.5 %)
were above the level of bleeding tendency at the peak (R-
C 5.39 ± 1.01, median 5.13) and 66 (42 %) were below the
prevention cut-off at the trough (R-C 1.31 ± 0.18, median
1.35), which indicates that treatment with rivaroxaban
warrants dose adjustment. The paper by Beyer-
Westendorf et al. [24], describe that in real life, rates of
rivaroxaban-related major bleeding may be lower and
that the outcome may at least not be worse than that of
major vitamin K antagonist bleeding. We assume that
in patients on rivaroxaban, routine measure of anti-
coagulant activity using a coagulometric method as R-C
could lower risk of bleeding and/or thromboembolism
compared with no routine coagulation monitoring. Our
proposal should be considered hypothesis-generating; it
requires further clinical studies to show that in real life,
this monitoring strategy actually reduces bleeding and
risk of ischemic stroke.
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